Abstract
Human stem cell-derived cardiomyocytes present numerous advantages over isolated primary cardiac cells or tissues to study action potential (AP) prolongation by drug candidates for cardiac safety studies. Human stem cell-derived cardiomyocytes (hSC-CMs) express ionic channels that underlie cardiac action potentials and exhibit typical electrophysiological and mechanical characteristics of native human cardiomyocytes. Here, we demonstrate that the hSC-CMs are optimal for assessing dl-sotalol- and quinidine-induced action potential repolarization delay and nifedipine-induced shortening of action potential repolarization, and thus hSC-CMs exhibit the required electrophysiological and pharmacological profile at the cellular level.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Cranfield PF (1977) Action potentials, afterpotentials, and arrhythmias. Circ Res 41:415–423
Rosen MR, Moak JP, Damiano B (1984) The clinical relevance of afterdepolarizations. Ann N Y Acad Sci 427:84–93
Weiss JN, Garfinkel A, Karagueuzian HS, Chen PS, Qu Z (2010) Early afterdepolarizations and cardiac arrhythmias. Heart Rhythm 7:1891–1899
Keating MT, Sanguinetti MC (2001) Molecular and cellular mechanisms of cardiac arrhythmias. Cell 104:569–580
Liu GX, Choi BR, Ziv O, Li W, de Lange E, Qu Z et al (2012) Differential conditions for early after-depolarizations and triggered activity in cardiomyocytes derived from transgenic LQT1 and LQT2 rabbits. J Physiol 590:1171–1180
Antzelevitch C, Sicouri S (1994) Clinical relevance of cardiac arrhythmias generated by afterdepolarizations. Role of M cells in the generation of U waves, triggered activity and torsade de pointes. J Am Coll Cardiol 23:259–277
Viswanathan PC, Rudy Y (1999) Pause induced early afterdepolarizations in the long QT syndrome: a simulation study. Cardiovasc Res 42:530–542
Carlsson L, Abrahamsson C, Andersson B, Duker G, Schiller-Lindhardt G (1993) Proarrhythmic effects of class III agent almokalant: importance of infusion rate. QT dispersion and early after depolarizations. Cardiovasc Res 27:2186–2193
Burashnikov A, Antzelevitch C (1998) Acceleration-induced action potential prolongation and early afterdepolarizations. J Cardiovasc Electrophysiol 9:934–948
El-Sherif N, Caref FB, Yin H, Restivo M (1996) The electrophysiological mechanism of ventricular arrhythmias in the long QT syndrome tri-dimensional mapping of activation and recovery patterns. Circ Res 79:474–492
Surawicz B (1989) Electrophysiological substrate for Torsade de pointes: dispersion of refractoriness or early afterdepolarizations. J Am Coll Cardiol 14:172–184
Verduyn SC, Vos MA, Van der Zande J, Van der Hulst FF, Wellens HJJ (1997) Role of interventricular dispersion of repolarization in acquired torsade-de-pointes arrhythmias: reversal by magnesium. Cardiovasc Res 34:453–463
Antzelevitch C, Shimizu W, Yan GX et al (1999) The M cell: its contribution to the ECG and to normal and abnormal electrical function of the heart. J Cardiovasc Electrophysiol 10:1124–1152
Brown AM, Rampe D (2000) Drug-induced long QT syndrome: is HERG the root of all evil? Pharm News 7:15–20
ICH Harmonized Tripartite Guideline (2005) The non-clinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals S7B. Recommended for adoption at step 4 of the ICH process on 12 May 2005 by the ICH Steering Committee. ICH; (http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S7B/Step4/S7B_Guideline.pdf)
ICH Harmonized Tripartite Guideline (2005) The clinical evaluation of QT/QTc Interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs E14. Recommended for adoption at step 4 of the ICH process on 12 May 2005 by the ICH Steering Committee. ICH; (http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E14/E14_Guideline.pdf)
Darpo B (2010) The thorough QT study four years after the implementation of the ICH E14 guidance. Br J Pharmacol 159:49–57
E14 Implementation Working Group ICH E14 Guideline (2012) The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs questions & answers (R1) (http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E14/ E14_Q_As_R1_step4.pdf)
Sugiyama A, Hashimoto H, Nakamura Y, Fujita T, Kumagai Y (2014) QT/QTc study conducted in Japanese adult healthy subjects: a novel xanthine oxidase inhibitor topiroxostat was not associated with QT prolongation. J Clin Pharmacol 54(4):446–452
Giorgi MA, Bolaños R, Gonzalez CD, Di Girolamo G (2010) QT interval prolongation: preclinical and clinical testing arrhythmogenesis in drugs and regulatory implications. Curr Drug Saf 5:54–57
Rechanneling the cardiac proarrhythmia safety paradigm (2014) A meeting report from the Cardiac Safety Research Consortium. Am Heart J 167:292–300
Clements M, Thomas N (2014) High-throughput multi-parameter profiling of electrophysiological drug effects in human embryonic stem cell derived cardiomyocytes using multi-electrode arrays. Toxicol Sci 140(2):445–461
Pen S, Lacerda AE, Kirsch GE, Brown AM, Bruening-Wright A (2010) The action potential and comparative pharmacology of stem cell- derived human cardiomyocytes. J Pharmacol Toxicol Methods 61(3):277–286
Ma J et al (2011) High purity human-induced pluripotent stem cell-derived cardiomyocytes: electrophysiological properties of action potential and ionic currents. Am J Physiol Heart Circ Physiol 301:H2006–H2017
Sanguinetti MC, Changan J, Curran MC, Keating MT (1995) A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the Ikr potassium channel. Cell 81(2):299–307
Sanguinetti MC, Tristani- Firouzi M (2006) hERG potassium channels and cardiac arrhythmia. Nature 440:463–469
Acknowledgments
We thank Shimin Wang for collecting the action potential data.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Science+Business Media New York
About this protocol
Cite this protocol
Renganathan, M., Wei, H., Zhao, Y. (2017). Cardiac Action Potential Measurement in Human Embryonic Stem Cell Cardiomyocytes for Cardiac Safety Studies Using Manual Patch-Clamp Electrophysiology. In: Clements, M., Roquemore, L. (eds) Stem Cell-Derived Models in Toxicology. Methods in Pharmacology and Toxicology. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-6661-5_3
Download citation
DOI: https://doi.org/10.1007/978-1-4939-6661-5_3
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-6659-2
Online ISBN: 978-1-4939-6661-5
eBook Packages: Springer Protocols